ABBRIVIATED NEW DRUG PPLICATION (ANDA)

SEMINAR ON:. ABBRIVIATED NEW DRUG PPLICATION (ANDA). Presented by: Nagori Stavan Arunkumar Department of Pharmaceutics L.M.College of Pharamcy. ANDA. Pool of topics:. Introduction History of ANDA Guidelines available for ANDA Filling of ANDA

Share Presentation

Embed Code

Link

• pharmaceutics l m college
• drug substance
• expiration date
• data files
• generic drug exclusivity
• average saving

chaz + Follow

ABBRIVIATED NEW DRUG PPLICATION (ANDA)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

Presentation Transcript

1. SEMINAR ON: ABBRIVIATED NEW DRUG PPLICATION (ANDA) Presented by: Nagori Stavan Arunkumar Department of Pharmaceutics L.M.College of Pharamcy
2. ANDA Pool of topics: • Introduction • History of ANDA • Guidelines available for ANDA • Filling of ANDA • Manufacturing and control requirements of the ANDA • 180 days exclusitivity under Hatch Waxman amendment • Concept of Paragraph I to IV • Substantially complete ANDA • House keeping regulation • Patent expiration regulation • Triggering period • Waivers of exclusitivity • 505(b)(2) application • Supplemental new drug applications • Case studies • List of ANDA approved • 2006 pending ANDA • ANDA filed by or with Indian Pharmaceutical company • List of references
3. ANDA 1. Introduction ANDA contains data submitted to FDA's Center for Drug evaluation and Research, Office of Generic Drugs, for review and ultimate approval of a generic drug product. Once ANDA is approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, low cost alternative to the American public. A generic drug product is the one that is comparable to an innovator drug product in dosage form, strength, route of administration, quality, performance characteristics and intended use.
4. ANDA • All approved products, both innovator and generic, are listed in FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). • Generic drug applications are termed "abbreviated" • Use of bioequivalence as the base for approving generic drug products was established by the "Drug Price Competition and Patent Term Restoration Act of 1984," also known as the WAXMAN-HATCH ACT.
5. ANDA 2. HISTORY OF ANDA: • In 1938, proof of safety • In 1962, “THE KEFAUVER HARIS AMENDMENTS” • “THE KEFAUVER HARIS AMENDMENTS” led to “DRUG EFFICACY STUDY IMPLEMENTATION (DESI)”. • FDA’s realization • Mid 1966 notice in federal Register • DESI review ultimately led to evolution of ANDA concept.
6. ANDA • On April 24th 1970, the ANDA policy was published with exception of DESI pending list drugs and exempt as per court order • In November 1984, The Drug Price Competition and Patent Term Restoration Act. • Title 1: ANDA regardless of time before or after 1962 • Title 2: Patent extension for life lost • Title 3: Textile and wood products • In April, 1992 FDA finalized the regulations outlining the requirements for ANDAs.
7. ANDA • On November 21, 1997 Modernization Act was signed. • Section 506A-Changes for approved ANDA/NDA • Hatch-Waxman Amendments
8. ANDA 3. GUIDELINES AVAILABLE FOR ANDA: • Guidelines describe format & content for the following sections. • Application summary • Chemistry, Manufacturing and controls section • Non clinical pharmacology and toxicology section • Human pharmacokinetics & bioavailability section • Clinical and statically section • Microbiology section
9. ANDA • Guidelines available for ANDA includes: • Organization of ANDA • Electronic submission of data for ANDA • Submission of archival copy of application in Microfiche • Guideline for impurities in drug substances • Guideline for submitting supporting documentation for the Manufacture of Drug substance. • Guideline for submitting supporting documentation for the Manufacture of finished dosage forms.
10. ANDA • Guideline for submitting supporting documentation for stability studies of Human drugs and Biologics. • Guideline for packaging • Guidelines for changes in approved ANDA and NDA • Variations in Drug Products that may be included in a single ANDA • 180 days exclusivity under Hatch Waxman amendment • Guidelines for alternate source of API in pending ANDAs • Post marketing reporting of Adverse Drug reactions • Guidelines for changes in approved ANDA and NDA
11. ANDA 4. FILING OF ANDA:
12. ANDA • Proper organization • Proper format, clear table of contents, correct folders (jackets), correct tabulation and pagination • Detail’s under 21 CFR 314.50, 21 CFR 314.94 and 21 CFR 314.440 • OGD’s recommendation of bioequivalence, chemistry and labeling portions of an application
13. ANDA Paper based filing of ANDA: • Application copies and general format: • Submit Archival (reference, retained and official approved copy) and filed copy (duplicate, used by FDA investigators) in english • Translation copy with original reference copy
14. ANDA • Review copy (duplicate, FDA viewer, destroyed) in 2 sets of binders (jackets) • In first binder CMC • In another BE data • Remaining data (table of contents, labeling) in both • Consistency in color coding binders, volume size and specifications, size and quality of paper
15. ANDA
16. ANDA
17. ANDA II. Cover letter: • Purpose of submission • Type of submission (ANDA, amendment, supplement, annual report, or resubmission of a previously withdrawn application) • Name, title, address and signature of applicant • Proprietary name (if any) and name of drug product • Number of volumes submitted • Commitment to resolution of any issues identified in the methods validation process after approval • Statement that the application or a portion of the submission is in electronic process after approval • Clearly identify submissions that contain sterility assurance data
18. ANDA III. Table of content<(21 CFR 314509B)>:

• Related
• More by User

DRUG DISCOVERY – NEW DRUG DEVELOPMENT PROCESS

DRUG DISCOVERY – NEW DRUG DEVELOPMENT PROCESS. BY. Dr. BASAVARAJ K. NANJWADE. Department of Pharmaceutics K L E UNIVERSITY JN MEDICAL COLLEGE BELGAUM – 590010 E-mail: bknanjwade@yahoo.co.in. DRUG.

1.54k views • 55 slides

NEW DRUG DEVELOPMENT

This ppt describes the process of new drug development.

1.37k views • 65 slides

New Drug Update 2012

New Drug Update 2012. Nancy Letassy, PharmD, CDE Professor University of Oklahoma College of Pharmacy. 2012. New Molecular entities. Belviq ® (locaserin).

1.19k views • 75 slides

Cardiovascular New Drug Update

Cardiovascular New Drug Update. C. Wayne Weart, Pharm D, FASHP, FAPhA, BCPS Professor of Clinical Pharmacy and Outcome Sciences South Carolina College of Pharmacy Professor of Family Medicine Medical University of South Carolina Charleston, South Carolina weartcw@musc.edu.

1.26k views • 104 slides

NDA NEW DRUG APPLICATION

NDA NEW DRUG APPLICATION. 1/50. NEW DRUG APPLICATION. Introduction :

1.91k views • 50 slides

New Drug Update 2013

New Drug Update 2013. Armando Zuniga, Pharm.D. Drug Information Specialist INTEGRIS Southwest Medical Center. Cardiology / Vascular Disease. Mipomersen (Kynamro). Inhibitor of apolipoprotein B-100 synthesis indicated to treat homozygous familial hypercholesterolemia (HoFH)

950 views • 40 slides

New Jersey Drug Epidemic

New Jersey Drug Epidemic. Junior Health - 2013. New jersey drug epidemic. http://www.northjersey.com/specialreports/heroin_bergen_paterson_drugs_2013.html#ooid=5vZWtmYjqsdVqUypmfN7Zc8cBMPHUuk _. New jersey drug epidemic. Two year probe recently unveiled escalating epidemic in New Jersey

244 views • 7 slides

New Drug Approval Process

New Drug Approval Process. FDA Approvals. It takes 12 years and over $350 million to get a new drug from the laboratory onto the pharmacy shelf. Once a company develops a drug, it undergoes 3 ½ of laboratory testing,

715 views • 16 slides

A PPLICATION OF

A PPLICATION OF. M OLECULAR B IOLOGY T ECHNIQUES. IN A STROBIOLOGY. R ICCARDO S . G ATTA Ph.D. Molecular Genetics, I.C.G.E.B. New Delhi , Reg’d Pharmacist. J ULIAN C HELA- F LORES The Abdus Salam International Centre for Theoretical Physics

232 views • 10 slides

new jersey drug rehab

Garden State Treatment Center https://www.gardenstatetreatmentcenter.com - Located in the heart of Northern New Jersey, Garden State Treatment Center is an outpatient and partial care addiction treatment facility that offers nuanced levels of care for individuals struggling with the horrors of substance abuse. It is our explicit goal to help addicted clients rebuild their lives from the inside out and reintegrate themselves back into society. #new #jersey #drug #rehab #alcohol #addiction #treatment

NEW JERSEY DRUG LAWYER

If you are facing drug charges in New Jersey then read this infographic to know how an experiencedu00a0New Jersey drug lawyeru00a0at Andres Mejer Law can protect your future.u00a0For more details contact us at 732-945-8745.